Neurocrine Biosciences (NBIX) Other Operating Expenses (2009 - 2026)

Over the trailing twelve months to Sep 30, 2026, Neurocrine Biosciences reported Other Operating Expenses of $1.3 billion, up 37.5% year-over-year; for FY2025, it was $1.03 billion, up 38.9% from FY2024.

• Other Operating Expenses has increased in each of the last four years, with a five-year compound annual growth rate of 18.6% (FY2020 to FY2025).
• Going back by year, Other Operating Expenses was $743.6 million in FY2024 (+4.9%), $708.9 million in FY2023 (+52.8%), $463.8 million in FY2022 (+7.0%) and $433.4 million in FY2021 (-1.4%).
• The Q3 2026 figure represents the highest quarterly Other Operating Expenses in data going back to Q2 2010.
• Year-over-year, Other Operating Expenses has increased for ten consecutive quarters, with growth averaging 37.7% over the last eight quarters.
• The fastest year-over-year change in Other Operating Expenses over five years came in Q4 2021 (growth of 181.4%), and the weakest in Q1 2024 (a decline of 41.6%).
• Business Quant data shows NBIX's Other Operating Expenses at $344.6 million (Q2 2026), $288.8 million (Q1 2026) and $272.2 million (Q4 2025) in the three quarters before Q3 2026.